BMJ Open (Jun 2021)

Socioeconomic inequality in oral anticoagulation therapy initiation in patients with atrial fibrillation with high risk of stroke: a register-based observational study

  • Sam Riahi,
  • Søren Paaske Johnsen,
  • Gregory YH Lip,
  • Elin Danielsen Lunde,
  • Albert Marni Joensen,
  • Søren Lundbye-Christensen,
  • Kirsten Fonager,
  • Mogens Lytken Larsen

DOI
https://doi.org/10.1136/bmjopen-2021-048839
Journal volume & issue
Vol. 11, no. 5

Abstract

Read online

Objective The study aimed to examine the association between socioeconomic factors (SEFs) and oral anticoagulation (OAC) therapy and whether it was influenced by changing guidelines. We hypothesised that inequities in initiation of OAC reduced over time as more detailed and explicit clinical guidelines were issued.Design Register-based observational study.Settings All Danish patients with an incident hospital diagnosis of atrial fibrillation (AF), aged ≥30 years old and with high risk of stroke from 1 May 1999 to 2 October 2015 were included. Absolute risk differences (RD) (95% CI) were used to measure the association.Participants 154 448 patients (mean age 78.2 years, men 47.3%).Exposure Education, family income and cohabiting status were the SEFs used as exposure.Outcome A prescription of OAC within −30 to +90 days of baseline (incident AF).Results During 2002–2007, the crude RD of initiation of OAC for men with high education was 14.9% (12.8 to 16.9). Inequality reduced when new guidelines were published, and in 2013–2016 the crude RD was 5.6% (3.5 to 7.7). After adjusting for age, the RD substantially reduced. The same pattern was seen for cohabiting status, while inequality was smaller and more constant for income.Conclusion Patients with low income, low education and living alone were associated with lower chance of being initiated with OAC. For education and cohabiting status, the crude difference reduced around 2011, when more detailed clinical guidelines were implemented in Denmark. Our results indicate that new guidelines might reduce inequality in OAC initiation and that new, high-cost drugs increase inequality.